Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.

NCT00617461 is registered in ClinicalTrials.gov with XenoPort, Inc. as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00617461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Study PXN110527: The Investigation of the Efficacy and Pharmacokinetics of XP13512 in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN) Who Have Had an Inadequate Response to Gabapentin Treatment.
Lead sponsor
XenoPort, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2008
Completion date
July 31, 2009
Enrollment
96 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.